Nervous System and Brain Disorders

Prof. Hagit Eldar-Finkelman

GSK-3 and neurodegeneration

The research in Prof. Eldar-Finkelman’s laboratory is focused on the development of new innovative therapeutics addressing unmet needs in the neurodegenerative disorders arena. A particular interest is given to the protein kinase, glycogen synthase kinase3 (GSK-3), as a prominent drug target for treating neurodegeneration. They combine expertise in chemistry, biology, and https://heflab.com/ computational modeling to design drugs with unique inhibition modality. The team’s goal is to ultimately produce beneficial therapeutics for clinical practice.

Prof. Eldar-Finkelman, PhD, obtained her BSc in Chemistry from the Hebrew University of Jerusalem, and her MSc in Physical Chemistry and PhD in Life Sciences at the Weizmann Institute. Her postdoctoral work was conducted with the Nobel Prize Laureate Edwin G. Krebs at the University of Washington in Seattle. She then became an Assistant Professor at the Harvard Medical School in the Division of Women’s Health and then joined TAU. Eldar-Finkelman was a visiting scientist at MBL Woods Hole, Cape Code; EMBL-EBI Hinxton, UK; Perelman School of Medicine, University of Pennsylvania, Philadelphia; and at Rockefeller University, NYC. Her academic activities include representing the University in the InterUniversity Forum for Medical Sciences, in the National Council for Experiments in Animals Subjects, and in the State Control Committee in the Knesset. She is part of the Taube-Koret Global Collaboration in Neurodegenerative Diseases.